[go: up one dir, main page]

AR034716A1 - Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido - Google Patents

Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido

Info

Publication number
AR034716A1
AR034716A1 ARP020102447A ARP020102447A AR034716A1 AR 034716 A1 AR034716 A1 AR 034716A1 AR P020102447 A ARP020102447 A AR P020102447A AR P020102447 A ARP020102447 A AR P020102447A AR 034716 A1 AR034716 A1 AR 034716A1
Authority
AR
Argentina
Prior art keywords
complex
osteoclastogenesis
polisacarido
inhibiting factor
includes inhibiting
Prior art date
Application number
ARP020102447A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of AR034716A1 publication Critical patent/AR034716A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un complejo que comprende por lo menos una sustancia seleccionada del grupo que consiste de factor inhibidor de osteoclastogénesis, OCIF, análogos del mismo y variantes del mismo, el cual se une a por lo menos una sustancia seleccionada del grupo que consiste de polisacáridos y derivados de los mismos, muestra retención prolongada en la corriente sanguínea después de su administración, haciéndolo útil en el tratamiento y profilaxis de enfermedades metabólicas óseas
ARP020102447A 2001-06-29 2002-06-28 Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido AR034716A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001198985 2001-06-29

Publications (1)

Publication Number Publication Date
AR034716A1 true AR034716A1 (es) 2004-03-17

Family

ID=19036337

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102447A AR034716A1 (es) 2001-06-29 2002-06-28 Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido

Country Status (22)

Country Link
US (3) US20030045456A1 (es)
EP (1) EP1270015A3 (es)
KR (1) KR20030003124A (es)
CN (1) CN1442201A (es)
AR (1) AR034716A1 (es)
AU (1) AU783126B2 (es)
BR (1) BR0202439A (es)
CA (1) CA2392383A1 (es)
CO (1) CO5390084A1 (es)
CZ (1) CZ20022231A3 (es)
HK (1) HK1048762A1 (es)
HU (1) HUP0202119A2 (es)
IL (1) IL150448A0 (es)
MX (1) MXPA02006511A (es)
NO (1) NO20023144L (es)
PA (1) PA8549401A1 (es)
PE (1) PE20030254A1 (es)
PL (1) PL354799A1 (es)
RU (1) RU2232594C2 (es)
SG (1) SG98059A1 (es)
SK (1) SK9492002A3 (es)
ZA (1) ZA200205164B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
CA2347107A1 (en) 1998-10-28 2000-05-04 Shinichi Mochizuki Bone-pathobolism treating agent
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
AU2003208621A1 (en) * 2002-03-01 2003-09-16 Sankyo Company, Limited A pharmaceutical composition
JP4430403B2 (ja) 2002-04-10 2010-03-10 メルク セローノ ソシエテ アノニム 線維化疾患の治療および／または予防のためのオステオプロテゲリンの使用
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
RU2323227C2 (ru) * 2003-03-24 2008-04-27 Санкио Компани Лимитед Полимерные модификаторы и фармацевтические композиции
KR100840830B1 (ko) * 2006-09-03 2008-06-23 재단법인서울대학교산학협력재단 고분자 히알루론산을 포함하는 골흡수 저해용 조성물
RU2370271C2 (ru) * 2006-11-22 2009-10-20 Государственное учреждение гематологический научный центр Российской академии медицинских наук (ГУ ГНЦ РАМН) Способ обнаружения комплексов между гепаринами и поликатионами
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
CN115594776B (zh) * 2022-09-19 2024-03-15 山东大学 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207A (en) * 1845-09-27 lewis
US216297A (en) * 1879-06-10 Improvement in ironing-stands
US139325A (en) * 1873-05-27 Improvement in carriage-springs
US45456A (en) * 1864-12-13 Improved apparatus for carbureting air
US31725A (en) * 1861-03-19 Improvement in cultivators
US181418A (en) * 1876-08-22 Improvement in gas apparatus
TW318142B (es) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
CN1183159C (zh) * 1997-09-24 2005-01-05 三共株式会社 破骨细胞形成抑制因子单克隆抗体、其用途和试剂盒
EP1087977B1 (en) * 1998-06-15 2003-01-08 Takeda Chemical Industries, Ltd. Thienodipyridine derivatives, production and use thereof
CA2347107A1 (en) * 1998-10-28 2000-05-04 Shinichi Mochizuki Bone-pathobolism treating agent
ES2287028T3 (es) * 1999-09-03 2007-12-16 Amgen Inc. Composiciones y metodos para la prevencion o el tratamiento de cancer y de la perdida osea asociada con el cancer.
EP1379127B1 (en) * 2000-09-28 2013-04-17 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
AU2003208621A1 (en) * 2002-03-01 2003-09-16 Sankyo Company, Limited A pharmaceutical composition

Also Published As

Publication number Publication date
CA2392383A1 (en) 2002-12-29
CO5390084A1 (es) 2004-04-30
BR0202439A (pt) 2003-06-10
US20030139325A1 (en) 2003-07-24
NO20023144L (no) 2002-12-30
RU2232594C2 (ru) 2004-07-20
US20060084595A1 (en) 2006-04-20
MXPA02006511A (es) 2004-08-11
SK9492002A3 (en) 2003-02-04
PL354799A1 (en) 2002-12-30
NO20023144D0 (no) 2002-06-28
HUP0202119A2 (hu) 2003-04-28
AU783126B2 (en) 2005-09-29
HU0202119D0 (es) 2002-08-28
PA8549401A1 (es) 2003-07-28
SG98059A1 (en) 2003-08-20
HK1048762A1 (en) 2003-04-17
ZA200205164B (en) 2003-03-24
CN1442201A (zh) 2003-09-17
US20030045456A1 (en) 2003-03-06
CZ20022231A3 (cs) 2003-02-12
EP1270015A2 (en) 2003-01-02
PE20030254A1 (es) 2003-03-19
KR20030003124A (ko) 2003-01-09
EP1270015A3 (en) 2004-02-25
IL150448A0 (en) 2002-12-01
RU2002117385A (ru) 2004-01-27
AU5071902A (en) 2003-01-02

Similar Documents

Publication Publication Date Title
EA200600190A1 (ru) Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона
EA200900733A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
AR034716A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
BR0015188A (pt) Composições farmacêuticas
AR050418A1 (es) Dosificacion fija de anticuerpos her
DK1576970T3 (da) Intraluminal indretning med en coating, der indeholder et terapeutisk middel
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
CR7928A (es) Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension
WO2005065646A3 (en) Novel drug compositions and dosage forms
UY27350A1 (es) Azaindoles
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
AR033175A1 (es) Usos farmaceuticos de bisfosfonatos
AR045161A1 (es) Derivados de quinazolina
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
AR109263A2 (es) Composición que comprende moxidectina
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
ES2190081T3 (es) Derivados del triazol, un procedimiento para su preparacion y los medicamentos que los contienen.
CL2004000452A1 (es) Uso de un compuesto antiepileptico que contiene propiedades de alivio del dolor y dos o mas compuestos del grupo formado por antagonista del nmda selectivos de subtipo, analgesicos, nsaid, y combinaciones de ellos, para la preparacion de un medicamen
CR6834A (es) Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo
ECSP066685A (es) Composición que comprende un extracto acuoso de hojas de vid roja y un agente que mejora la circulación sanguínea para el tratamiento de insuficiencias venosas crónicas
AR038632A1 (es) Composicion farmaceutica
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose

Legal Events

Date Code Title Description
FB Suspension of granting procedure